Comorbid disorders and therapy of persistent postural perceptual dizziness

E. N. Zastenskaya, L. M. Antonenko
{"title":"Comorbid disorders and therapy of persistent postural perceptual dizziness","authors":"E. N. Zastenskaya, L. M. Antonenko","doi":"10.14412/2074-2711-2023-466-73","DOIUrl":null,"url":null,"abstract":"Persistent postural perceptual dizziness (PPPD) is the most common cause of vague chronic vertigo and severely limits patients' quality of life.Limited data are available on comorbidities, the typical treatment of patients with PPPD, and the efficacy of combination therapy for PPPD.Objective: to identify comorbid disorders and evaluate the efficacy of complex therapy in patients with PPPD.Material and methods. Sixty patients (mean age 42.5±13.8 years) with PPPD were studied. All patients were prescribed complex treatment that included antidepressants (selective serotonin reuptake inhibitors), vestibular exercises, and an educational program. In 28 patients, Arlevert (combination of cinnarizine 20 mg + dimenhydrinate 40 mg) was used as drug therapy. A clinical otoneurologic examination, videonystagmography, assessments by Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Spielberger State-Trait Anxiety Inventory (STAI), Dizziness Handicap Inventory (DHI) and otoneurologic examination were performed at baseline and at the end of treatment (mean, one month).Results. All patients had previous misdiagnoses, among which vertebrobasilar insufficiency and chronic cerebral ischemia predominated. Thirty two (53.33%) patients with PPPD had anxiety-depressive disorders (ADD) as the main comorbidity, 20 (33.33%) patients had migraine, 8 (13.33%) patients had previously had peripheral vestibular disorders that were not diagnosed. The severity of dizziness according to the otoneurological questionnaire and the DHI decreased after one month of therapy in the group with PPPD and ADD from 44.00±16.80 to 29.6±12.80 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 49.20±14.04 to 31.60±17.69 points (p<0.001), in the group with PPPD and migraine – from 43.58±16.28 to 28.50±7.20 points (p<0.001). The severity of anxiety and depression according to BAI decreased in the group with PPPD and ADD from 30.00±6.99 to 16.12±4.16 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 28.40±8.35 to 16.60±4.62 points (p<0.001), in the group with PPPD and migraine – from 24.11±3.80 to 14.26±3.43 points (p<0.001). The severity of depression according to BDI decreased in the group with PPPD and ADD from 9.62±5.26 to 6.25±3.20 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 14.80±8.26 to 8.40±5.37 points (p<0.001), in the group with PPPD and migraine – from 11.32±5.10 to 6.53±3.44 points (p<0.001). The severity of anxiety according to HADS decreased in the group with PPPD and ADD from 13.75±3.20 to 9.25±2.43 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 12.40±5.77 to 7.80±3.83 points (p<0.001), in the group with PPPD and migraine – from 14.26±3.16 to 8.74±2.18 points (p<0.001).The severity of depression according to HADS decreased in the group with PPPD and ADD from 4.88±4.12 to 3.88±3.09 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 8.40±3.58 to 5.60±2.88 points (p<0.001), in the group with PPPD and migraine – from 5.74±3.11 to 3.47±2.32 points (p<0.001). Situational anxiety according to STAI decreased in the group with PPPD and ADD from 47.62±6.57 to 40.12±3.68 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 58.20±7.85 to 48.00±7.65 points (p<0.001), in the group with PPPD and migraine – from 46.26±7.01 to 35.68±5.11 points (p<0.001). Personal anxiety according to STAI decreased in the group with PPPD and ADD from 52.25±10.73 to 42.12±7.06 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 58.40±5.64 to 48.60±6.77 points (p<0.001), in the group with PPPD and migraine – from 53.32±8.78 to 40.63±5.60 points (p<0.001).Conclusion. Patients with PPPD are often misdiagnosed with cerebrovascular disease. The most common comorbid disorders in PPPD are anxiety disorders and migraine, and less commonly peripheral vestibular disorders. An integrated approach to the management of patients with PPPD, including treatment of comorbid disorders, is effective.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology, neuropsychiatry, Psychosomatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14412/2074-2711-2023-466-73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Persistent postural perceptual dizziness (PPPD) is the most common cause of vague chronic vertigo and severely limits patients' quality of life.Limited data are available on comorbidities, the typical treatment of patients with PPPD, and the efficacy of combination therapy for PPPD.Objective: to identify comorbid disorders and evaluate the efficacy of complex therapy in patients with PPPD.Material and methods. Sixty patients (mean age 42.5±13.8 years) with PPPD were studied. All patients were prescribed complex treatment that included antidepressants (selective serotonin reuptake inhibitors), vestibular exercises, and an educational program. In 28 patients, Arlevert (combination of cinnarizine 20 mg + dimenhydrinate 40 mg) was used as drug therapy. A clinical otoneurologic examination, videonystagmography, assessments by Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Spielberger State-Trait Anxiety Inventory (STAI), Dizziness Handicap Inventory (DHI) and otoneurologic examination were performed at baseline and at the end of treatment (mean, one month).Results. All patients had previous misdiagnoses, among which vertebrobasilar insufficiency and chronic cerebral ischemia predominated. Thirty two (53.33%) patients with PPPD had anxiety-depressive disorders (ADD) as the main comorbidity, 20 (33.33%) patients had migraine, 8 (13.33%) patients had previously had peripheral vestibular disorders that were not diagnosed. The severity of dizziness according to the otoneurological questionnaire and the DHI decreased after one month of therapy in the group with PPPD and ADD from 44.00±16.80 to 29.6±12.80 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 49.20±14.04 to 31.60±17.69 points (p<0.001), in the group with PPPD and migraine – from 43.58±16.28 to 28.50±7.20 points (p<0.001). The severity of anxiety and depression according to BAI decreased in the group with PPPD and ADD from 30.00±6.99 to 16.12±4.16 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 28.40±8.35 to 16.60±4.62 points (p<0.001), in the group with PPPD and migraine – from 24.11±3.80 to 14.26±3.43 points (p<0.001). The severity of depression according to BDI decreased in the group with PPPD and ADD from 9.62±5.26 to 6.25±3.20 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 14.80±8.26 to 8.40±5.37 points (p<0.001), in the group with PPPD and migraine – from 11.32±5.10 to 6.53±3.44 points (p<0.001). The severity of anxiety according to HADS decreased in the group with PPPD and ADD from 13.75±3.20 to 9.25±2.43 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 12.40±5.77 to 7.80±3.83 points (p<0.001), in the group with PPPD and migraine – from 14.26±3.16 to 8.74±2.18 points (p<0.001).The severity of depression according to HADS decreased in the group with PPPD and ADD from 4.88±4.12 to 3.88±3.09 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 8.40±3.58 to 5.60±2.88 points (p<0.001), in the group with PPPD and migraine – from 5.74±3.11 to 3.47±2.32 points (p<0.001). Situational anxiety according to STAI decreased in the group with PPPD and ADD from 47.62±6.57 to 40.12±3.68 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 58.20±7.85 to 48.00±7.65 points (p<0.001), in the group with PPPD and migraine – from 46.26±7.01 to 35.68±5.11 points (p<0.001). Personal anxiety according to STAI decreased in the group with PPPD and ADD from 52.25±10.73 to 42.12±7.06 points (p<0.001), in the group with PPPD and peripheral vestibular disorders – from 58.40±5.64 to 48.60±6.77 points (p<0.001), in the group with PPPD and migraine – from 53.32±8.78 to 40.63±5.60 points (p<0.001).Conclusion. Patients with PPPD are often misdiagnosed with cerebrovascular disease. The most common comorbid disorders in PPPD are anxiety disorders and migraine, and less commonly peripheral vestibular disorders. An integrated approach to the management of patients with PPPD, including treatment of comorbid disorders, is effective.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
持续性体位性知觉头晕的合并症及治疗
持续性体位性知觉眩晕(PPPD)是模糊性慢性眩晕最常见的原因,严重限制了患者的生活质量。关于合并症、PPPD患者的典型治疗以及PPPD联合治疗的疗效的数据有限。目的:探讨PPPD患者的合并症,评价综合治疗的疗效。材料和方法。对60例PPPD患者(平均年龄42.5±13.8岁)进行了研究。所有患者都接受了包括抗抑郁药(选择性血清素再摄取抑制剂)、前庭运动和教育计划在内的综合治疗。28例患者采用Arlevert(联合肉桂利嗪20 mg +苯海明40 mg)作为药物治疗。在治疗开始时和治疗结束时(平均1个月)进行临床耳神经检查、视频震颤图、医院焦虑抑郁量表(HADS)、贝克抑郁量表(BDI)、贝克焦虑量表(BAI)、斯皮尔伯格状态-特质焦虑量表(STAI)、头晕障碍量表(DHI)和耳神经检查。所有患者既往均有误诊,其中以椎基底动脉功能不全和慢性脑缺血为主。32例(53.33%)PPPD患者共患焦虑抑郁障碍(ADD), 20例(33.33%)合并偏头痛,8例(13.33%)既往有未确诊的外周前庭功能障碍。治疗1个月后,PPPD合并ADD组眩晕严重程度从44.00±16.80分降至29.6±12.80分(p<0.001), PPPD合并前庭外周疾病组从49.20±14.04分降至31.60±17.69分(p<0.001), PPPD合并偏头痛组从43.58±16.28分降至28.50±7.20分(p<0.001)。根据BAI, PPPD和ADD组的焦虑和抑郁严重程度从30.00±6.99分降至16.12±4.16分(p<0.001), PPPD和前神经外周障碍组从28.40±8.35分降至16.60±4.62分(p<0.001), PPPD和偏头痛组从24.11±3.80分降至14.26±3.43分(p<0.001)。根据BDI, PPPD和ADD组抑郁严重程度从9.62±5.26分降至6.25±3.20分(p<0.001), PPPD和前庭外周疾病组从14.80±8.26分降至8.40±5.37分(p<0.001), PPPD和偏头痛组从11.32±5.10分降至6.53±3.44分(p<0.001)。根据HADS, PPPD合并ADD组的焦虑严重程度从13.75±3.20分降至9.25±2.43分(p<0.001), PPPD合并前庭外周疾病组的焦虑严重程度从12.40±5.77分降至7.80±3.83分(p<0.001), PPPD合并偏头痛组的焦虑严重程度从14.26±3.16分降至8.74±2.18分(p<0.001)。根据HADS, PPPD和ADD组的抑郁严重程度从4.88±4.12分降至3.88±3.09分(p<0.001), PPPD和前庭外周疾病组的抑郁严重程度从8.40±3.58分降至5.60±2.88分(p<0.001), PPPD和偏头痛组的抑郁严重程度从5.74±3.11分降至3.47±2.32分(p<0.001)。根据STAI, PPPD和ADD组情境焦虑从47.62±6.57分下降到40.12±3.68分(p<0.001), PPPD和前庭外周疾病组从58.20±7.85分下降到48.00±7.65分(p<0.001), PPPD和偏头痛组从46.26±7.01分下降到35.68±5.11分(p<0.001)。PPPD合并ADD组的个人焦虑指数从52.25±10.73分降至42.12±7.06分(p<0.001), PPPD合并前庭外周障碍组从58.40±5.64分降至48.60±6.77分(p<0.001), PPPD合并偏头痛组从53.32±8.78分降至40.63±5.60分(p<0.001)。PPPD患者常被误诊为脑血管疾病。PPPD中最常见的合并症是焦虑症和偏头痛,以及不太常见的外周前庭疾病。综合治疗PPPD患者的方法是有效的,包括合并症的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acute cerebrovascular accidents in patients with new coronavirus infection COVID-19 Clinical case of an atypical course of autoimmune anti-NMDA encephalitis Neuropsychological assessment of the morphofunctional organization of humour perception processes Vestibular rehabilitation in complex therapy of vestibular vertigo (consensus of experts) Assessment of spasticity-related pain in cerebral palsy and the efficacy of its treatment with incobotulinumtoxin A (literature review)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1